Liver cancer is sometimes referred to as hepatic cancer or primary hepatic malignancy. It is the sixth most common type of cancer worldwide. Moreover, it is the fourth main cause of cancer-related deaths. 75% of primary liver malignancies are hepatocellular carcinomas (HCCs), making them the most prevalent kind. Liver cancer manifests as fever, weight loss, jaundice, and abdominal pain. Aflatoxin exposure, cirrhosis from alcohol, and hepatitis B and C infections are risk factors. Among the available treatment options include liver transplantation, radiation therapy, targeted therapy, and surgery. Moreover, the rising prevalence of the condition is anticipated to positively impact the pipeline landscape for liver cancer drugs.
Major companies involved in the liver cancer treatment market include Bristol-Myers Squibb, Adaptimmune and Merck Sharp & Dohme LLC. among others.
Leading drugs currently under the pipeline include AFPᶜ³³²T and Nivolumab, among others.
The increasing cases of liver cancer and the rising technological advancements are poised to positively influence the marginal zone lymphoma pipeline landscape.
The Liver Cancer Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into liver cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for liver cancer. The liver cancer report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The liver cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with liver cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to liver cancer.
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and has a complicated and multiple pathogenesis. One important stage in the viral carcinogenesis of HCC4 is cirrhosis. Chronic alcohol use, aflatoxin-B1-contaminated diet, and persistent hepatitis B (HBV) and C (HCV) viral infections have all been connected to the development of HCC. HBV can affect the development of liver cancer by increasing the expression of activating transcription factor 7 (ATF7), which promotes cell proliferation and inhibits apoptosis. Additionally, viral proteins can control cellular signaling pathways. HBV-induced hepatocarcinogenesis is caused by a combination of host-viral interactions, prolonged cycles of necrosis, inflammation, and regeneration, viral integration into the host genome, and the specific activation of oncogenic pathways by different viral proteins.
Small molecules are the most popular kind for treating liver cancer because of their capacity to effectively enter cells and target important oncogenic pathways. Small molecule tyrosine kinase inhibitors, such sorafenib and lenvatinib, are used to treat hepatocellular carcinoma (HCC) and decrease tumor growth and angiogenesis. Small molecules have superior oral bioavailability and systemic dispersion compared to oligonucleotides and peptides, which makes them more useful for treating liver cancer. Nevertheless, oligonucleotide and peptide-based treatments are being investigated for potential future developments. Further, the rising focus on the development of liver cancer emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
Globally, liver cancer ranks as the sixth most common type of cancer. There were 866,136 new cases in 2022. Asia is home to almost 75% of liver cancer cases, with China bearing more than 50% of the global burden. The country with the greatest incidence rate is Mongolia. Males typically have two to three times the incidence and fatality rates of females. The fourth most frequent cause of cancer-related fatalities worldwide is liver cancer. According to the American Cancer Society, 42,240 new cases are expected to be detected in the United States in 2025.
This section of the report covers the analysis of liver cancer drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials, with a substantial number of liver cancer drugs undergoing clinical development.
The drug molecule categories covered under liver cancer pipeline analysis include small molecules, biologics, peptides, and immunotherapies, among others. The liver cancer report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for liver cancer.
The EMR report for the liver cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed liver cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in liver cancer clinical trials:
Major drugs currently in the drug pipeline are as follows:
Adaptimmune's AFPᶜ³³²T is an investigational therapy for advanced hepatocellular carcinoma (HCC) and other tumors expressing alpha-fetoprotein (AFP). This approach involves modifying a patient's own T cells to express enhanced T-cell receptors (TCRs) targeting AFP, aiming to bolster the immune system's ability to attack cancer cells. In the Phase I clinical trial, AFPᶜ³³²T demonstrated an acceptable safety profile and potential anti-tumor activity, including a complete response in one patient. The trial is ongoing, with an estimated completion date in July 2025.
Nivolumab, marketed as Opdivo by Bristol-Myers Squibb, is an immunotherapy drug approved for treating hepatocellular carcinoma (HCC), the most common type of liver cancer. It functions as a PD-1 immune checkpoint inhibitor, enhancing the body's immune response against cancer cells. In the CheckMate -040 trial, Nivolumab demonstrated a 14.3% overall response rate in HCC patients previously treated with sorafenib, leading to its accelerated approval by the FDA. Ongoing studies continue to assess its efficacy in various liver cancer settings.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Liver Cancer Drug Report provides a strategic overview of the latest and future landscape of treatments for liver cancer. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the liver cancer pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share